FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
THURSDAY, Dec. 19, 2024 -- The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.
Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).
The FDA first announced two months ago that any shortage of the medications observed during the summer was over.
However, it was forced to "re-evaluate" that decision after demands by the Outsourcing Facilities Association (OFA), a trade group for compounding pharmacists, which sued the agency claiming that tirzepatide was still in short supply.
As long as the drug shortage was declared, compounding pharmacies were still eligible to produce their own versions of Zepbound/Mounjaro.
However, Thursday's FDA announcement effectively puts an end to that, and compounding pharmacies must now cease producing the lucrative drugs within a set time period.
For many compounding pharmacies that date is 60 days from today (Feb.18) and for "bulk" compounding pharmacies the date is 90 days away (March 19), the FDA said in a statement.
"FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe," the agency noted.
Eli Lilly, the maker of Zepbound and Mounjaro, had pushed back against the OFA's assertion that shortages of tirzepatide were still in place, and has also claimed that versions of the drug made by compounded pharmacies are often "untested, unapproved knockoffs," according to NBC News.
As for other popular GLP-1s, the FDA listed these ongoing shortages:
-
Dulaglutide (Trulicity) injection remains in shortage
-
Liraglutide (Saxenda) injection remains in shortage
Sources
- FDA announcement, Dec. 19, 2024
- NBC News
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Ozempic Pill Effective For Weight Loss
WEDNESDAY, Sept. 24, 2025 — A pill form of the blockbuster weight-loss drug Ozempic can help overweight or obese folks shed excess pounds, a new clinical trial has...
Weight-Loss Surgery Outperforms GLP-1 Drugs, Study Argues
FRIDAY, Sept. 19, 2025 — Cutting-edge drugs like Ozempic and Zepbound are all the rage for dropping excess pounds, but weight-loss surgery might have a better impact on...
Sepsis Risk Doubled With Type 2 Diabetes
FRIDAY, Sept. 19, 2025 — Type 2 diabetes appears to double a person’s risk for life-threatening sepsis, a new study says. Men and people under 60 with diabetes are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.